A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
NCT ID: NCT03459534
Last Updated: 2024-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
173 participants
INTERVENTIONAL
2018-06-25
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
NCT01511289
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
NCT01602952
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
NCT06665412
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT00519090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radotinib HCl
Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.
Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg.
Radotinib HCl
1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.
2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)
3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder
4. Storage conditions: Store in an airtight light proof container at room temperature.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radotinib HCl
1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.
2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)
3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder
4. Storage conditions: Store in an airtight light proof container at room temperature.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Chronic Phase Ph+ Chronic Myeloid Leukemia patients who failed or intolerance the previous TKIs therapy including Imatinib Imatinib
3. ECOG scale 0, 1 or 2
4. Chronic phase is defined as all of the following conditions that subjects meet.
* Blast in peripheral blood and bone marrow \<15%
* The sum of blast and promyelocyte in peripheral blood and bone marrow \<30%
* Basophil in peripheral blood \<20%
* Platelets count ≥50 × 10\^9/L (≥ 50,000/mm3) (But, transient prior therapy related thrombocytopenia \[\< 50 × 109/L (\< 50,000/mm3)\] is acceptable
* No evidence of involvement of extramedullary leukemia other than enlargements of liver and spleen
5. Patients who have adequate organ functions as defined below:
* Total bilirubin \< 1.5 × upper limit of normal (ULN)
* SGOT and SGPT \< 2.5× ULN
* Creatinine \< 1.5 × ULN
* Serum amylase and lipase ≤ 1.5 × ULN
* Alkaline Phosphatase ≤ 2.5 × ULN (only if not related to the tumor)
6. Women of childbearing potential should have a negative serum or urine pregnancy test within 14 days of the enrollment.
7. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month (4 weeks) after the last dose of investigational product in such a manner that the risk of pregnancy is minimized.
Exclusion Criteria
2. Patients with CCyR at the time of screening
3. Any below impaired cardiac function:
* LVEF \<45% or \< lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram at the site
* Patients who cannot have QT intervals measured according to ECG
* Complete left bundle branch block
* Patients with cardiac pacemakers
* Patients with congenital long QT syndrome or the family history of known long QT syndrome
* History of, or presence of symptomatic ventricular or atrial tachyarrhythmias
* Clinically significant resting bradycardia (\< 50 bpm)
* The mean QTcF \>450msec following three consecutive ECG tests at baseline
: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF \>450msec and the electrolyte is not within the normal range.
* Medical history of clinically confirmed myocardial infarction
* Medical history of unstable angina (within last 12 months)
* Other clinically significant cardiac disease
4. Patients with T315I point mutations
5. Patients with central nervous system involvement as cytopathologically confirmed
6. Severe or uncontrolled chronic disease
7. Significant medical history of congenital or acquired bleeding disorders that are not related to leukemia
8. Patients who previously received radiotherapy to at least 25% of the bodies with high portion of bone marrow
9. Patients who received the major surgery within 4 weeks before the initiation of the IP administration or who failed to recover from the surgery that was performed before then.
10. Patients who participated in other clinical study and are receiving any other IP.
11. Patients who cannot give consent to the clinical study.
12. Patients who have concurrently clinically significant primary malignancy
13. Patients currently receiving treatment with a strong CYP3A4 inhibitors or strong CYP3A4 inducers or therapeutic Cumarin derivatives and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs.
14. Patients who are currently receiving treatment with a medication that has the potential to prolong QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs. If subjects need to start such drug treatments during the study, they should contact the sponsor, IL-YANG PHARM. Co., Ltd.
15. Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product
16. Medical history of acute or chronic pancreatitis within the past one year
17. Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease
18. Patients known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \< 500 IU/mL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C patients can be enrolled.
19. Women patients that meet the following conditions should be excluded from the clinical study.
* Pregnancy
* Breastfeeding
* Pregnancy confirmed at screening pregnancy test
* Women of childbearing potential who is unwilling to use an appropriate method of contraception during the study
20. Men patients who are unwilling to use and appropriate method of contraception during the study
21. Patients who have hypersensitivity to active ingredient or any of the excipients of this investigational product
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Il-Yang Pharm. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dong Wook Kim
Role: PRINCIPAL_INVESTIGATOR
the Catholic University of Korea's St. Mary's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Territorial State Budgetary Institution
Barnaul, , Russia
Federal State Budgetary Institution of Science
Kirov, , Russia
Federal State Budgetary Institution
Moscow, , Russia
Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin
Moscow, , Russia
Federal State Budgetary Institution
Saint Petersburg, , Russia
Federal State Budgetary Institution
Saint Petersburg, , Russia
Uijeongbu Eulji Medical Center, Eulji University
Uijeongbu-si, Gyeonggi-do, South Korea
Ankara University Medical Faculty
Ankara, , Turkey (Türkiye)
Gazi University Medical Faculty
Ankara, , Turkey (Türkiye)
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
Istanbul, , Turkey (Türkiye)
Ege University Medical Faculty
Izmir, , Turkey (Türkiye)
Mersin University Medical Faculty
Mersin, , Turkey (Türkiye)
Ondokuz Mayis Univ. Med. Fac.
Samsun, , Turkey (Türkiye)
CI Cherkasy Regional Oncological Dispensary of CRC
Cherkassy, , Ukraine
CTPI Chernihiv Regional Oncological Dispensary
Chernihiv, , Ukraine
CI Dnipropetrovsk CMCH #4 OF Dnipropetrovsk RC
Dnipro, , Ukraine
Institute of CR of SI NSC of Radiation Medicine of NAMSU H&T Unit
Kyiv, , Ukraine
SI Institute of Blood Pathology and Transfusion Medicine of AMSU
Lviv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dong-Wook Kim, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-003810-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
RT51KRI03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.